Get the Stockscreener App
8.335
5.45%
-0.475
Dbv Technologies Adr stock is traded at $8.335, with a volume of 32,193.
It is down -5.45% in the last 24 hours and down -7.55% over the past month.
DBV Technologies SA is a clinical-stage specialty biopharmaceutical company focused on changing the field of immunotherapy by developing a novel technology platform called Viaskin. The therapeutic approach is based on epicutaneous immunotherapy or EPIT, its proprietary method of delivering biologically active compounds to the immune system through intact skin using Viaskin, an epicutaneous patch (i.e., a skin patch). Its main product candidate under development is Viaskin Peanut for the treatment of peanut-allergic patients. In addition, the company also has earlier-stage food allergy programs, including Viaskin Milk and Eosinophilic Esophagitis, or EoE.
See More
Previous Close:
$8.81
Open:
$8.56
24h Volume:
32,193
Relative Volume:
0.08
Market Cap:
$1.14B
Revenue:
-
Net Income/Loss:
$-102.09M
P/E Ratio:
-7.9381
EPS:
-1.05
Net Cash Flow:
$-108.72M
1W Performance:
-0.95%
1M Performance:
-7.55%
6M Performance:
+113.59%
1Y Performance:
+45.40%
1-Day Range:
$8.25
$8.675
1-Week Range:
$8.29
$9.92
52-Week Range:
$2.2045
$12.78
Dbv Technologies Adr Stock (DBVT) Company Profile
Name
Dbv Technologies Adr
Sector
Industry
Phone
33(0)155427878
Address
107 AVENUE DE LA REPUBLIQUE, CHATILLON
Compare DBVT with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
DBVT
Dbv Technologies Adr
|
8.36 | 239.88M | 0 | -102.09M | -108.72M | -1.05 |
|
ONC
Beone Medicines Ltd Adr
|
246.87 | 25.81B | 3.81B | -644.79M | -669.77M | -6.24 |
|
VRTX
Vertex Pharmaceuticals Inc
|
443.41 | 111.46B | 11.10B | -988.90M | -1.26B | -3.92 |
|
AKTX
Akari Therapeutics Plc Adr
|
1.32 | 40.37M | 0 | 0 | 0 | 0.00 |
|
VRNA
Verona Pharma Plc Adr
|
80.91 | 6.19B | 0 | -153.72M | -103.81M | -2.00 |
|
REGN
Regeneron Pharmaceuticals Inc
|
492.90 | 64.44B | 14.09B | 4.50B | 2.96B | 39.28 |
Dbv Technologies Adr Stock (DBVT) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Jan-04-23 | Upgrade | Societe Generale | Hold → Buy |
| Dec-16-22 | Downgrade | Goldman | Neutral → Sell |
| May-10-22 | Downgrade | Goldman | Buy → Neutral |
| Sep-14-21 | Upgrade | Societe Generale | Hold → Buy |
| Jan-22-21 | Downgrade | Societe Generale | Hold → Sell |
| Nov-02-20 | Upgrade | Societe Generale | Sell → Hold |
| Aug-06-20 | Downgrade | Societe Generale | Buy → Sell |
| Aug-05-20 | Reiterated | H.C. Wainwright | Buy |
| Mar-17-20 | Downgrade | Stifel | Buy → Hold |
| Jan-09-20 | Upgrade | Stifel | Hold → Buy |
| Dec-16-19 | Initiated | Citigroup | Buy |
| Sep-05-19 | Resumed | Morgan Stanley | Equal-Weight |
| Jun-17-19 | Initiated | Goldman | Buy |
| Dec-20-18 | Downgrade | Barclays | Overweight → Equal Weight |
| Dec-20-18 | Downgrade | BofA/Merrill | Buy → Underperform |
| Dec-20-18 | Downgrade | Jefferies | Buy → Hold |
| Dec-20-18 | Downgrade | Stifel | Buy → Hold |
| Oct-31-17 | Upgrade | Societe Generale | Sell → Hold |
| Oct-24-17 | Downgrade | Societe Generale | Buy → Sell |
| Oct-23-17 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| Jun-23-17 | Initiated | Deutsche Bank | Buy |
| Mar-16-17 | Upgrade | Societe Generale | Hold → Buy |
| Sep-26-16 | Initiated | JMP Securities | Mkt Outperform |
| Dec-03-15 | Initiated | Barclays | Overweight |
| Oct-23-15 | Initiated | BofA/Merrill | Buy |
View All
Dbv Technologies Adr Stock (DBVT) Latest News
DBV Technologies (NASDAQ:DBVT) Raised to Sell at The Goldman Sachs Group - Defense World
DBV Technologies (NASDAQ:DBVT) Now Covered by Analysts at The Goldman Sachs Group - Defense World
Goldman Sachs cuts DBV Technologies stock to Sell, target EUR1.30 - Investing.com India
Goldman Sachs reinstates DBV Technologies with sell rating, $7.25 target - Investing.com
Goldman Sachs reinstates DBV Technologies with sell rating, $7.25 target By Investing.com - Investing.com UK
DBV Technologies (NASDAQ:DBVT) Price Target Raised to $21.00 at JMP Securities - Defense World
European ADRs Rise On S&P Europe Select Index - Finimize
DBV Technologies’ SWOT analysis: peanut allergy treatment stock faces pivotal trial - Investing.com
European ADRs Slip As US Index Notes Mixed Gains And Losses - Finimize
European ADRs Show Optimism As Genfit Leads Gains - Finimize
Comparing DBV Technologies (NASDAQ:DBVT) and Maze Therapeutics (NASDAQ:MAZE) - Defense World
Are You Looking for a Top Momentum Pick? Why DBV Technologies S.A. (DBVT) is a Great Choice - Nasdaq
European ADRs Dip As Pharma And Tech Stocks See Mixed Results - Finimize
Combined General Meeting of June 11, 2025 - GlobeNewswire
DBV Technologies Sets Critical Shareholder Meeting: Key Documents Now Available - Stock Titan
European ADRs Show Modest Gains With Standout Performers - Finimize
StockNews.com Upgrades DBV Technologies (NASDAQ:DBVT) to “Hold” - Defense World
FY2025 EPS Forecast for DBV Technologies Boosted by Analyst - Defense World
What is HC Wainwright’s Estimate for DBVT Q2 Earnings? - Defense World
European ADRs Dip With Mixed Performances Across Key Sectors - Finimize
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of DBV Technologies S.A.DBVT - Barchart.com
HC Wainwright Issues Positive Forecast for DBV Technologies (NASDAQ:DBVT) Stock Price - Defense World
DBV Technologies to Participate in the Citizens JMP Life Sciences Conference - The Manila Times
DBV Technologies stock target raised to $16 by H.C. Wainwright - Investing.com Nigeria
DBV Technologies CEO Set for Key Presentation: How to Watch Live Fireside Chat at JMP Conference - Stock Titan
JMP Securities Boosts DBV Technologies (NASDAQ:DBVT) Price Target to $15.00 - Defense World
DBV Technologies (NASDAQ:DBVT) Earns Hold Rating from Analysts at StockNews.com - Defense World
DBV Technologies Reports First Quarter 2025 Financial Results - EIN News
European ADRs Show Strength With Genfit And Novo Nordisk Leading Gains - Finimize
DBV Technologies Secures Massive $306.9M Financing Despite Q1 Losses: Cash Runway Extended - Stock Titan
European ADRs Show Gains Despite Mixed Performances In Key Sectors - Finimize
European Stocks Shine In The US With Strong Gains - Finimize
StockNews.com Initiates Coverage on DBV Technologies (NASDAQ:DBVT) - Defense World
JMP maintains DBVT stock with $10 target, positive trial outlook - Investing.com
Vaxcyte (NASDAQ:PCVX) versus DBV Technologies (NASDAQ:DBVT) Critical Survey - The AM Reporter
DBV Technologies (NASDAQ:DBVT) & Vaxcyte (NASDAQ:PCVX) Critical Contrast - Defense World
European Stocks In The US Shine: Gains Led By Ericsson And Others - Finimize
DBV Technologies (NASDAQ:DBVT) Now Covered by Analysts at StockNews.com - Defense World
Dbv Technologies Adr Stock (DBVT) Financials Data
Revenue
Net Income
Cash Flow
EPS
Dbv Technologies Adr Stock (DBVT) Insider Trading
| Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
|---|---|---|---|---|---|---|---|
| Mohideen Pharis | Chief Medical Officer |
Jan 30 '25 |
Sale |
0.85 |
600 |
510 |
110,510 |
| Mohideen Pharis | Chief Medical Officer |
Nov 25 '24 |
Sale |
0.57 |
565 |
322 |
111,110 |
| Mohideen Pharis | Chief Medical Officer |
Nov 22 '24 |
Sale |
0.53 |
342 |
181 |
111,675 |
| Mohideen Pharis | Chief Medical Officer |
Nov 21 '24 |
Sale |
0.54 |
2,350 |
1,269 |
112,017 |
| Mohideen Pharis | Chief Medical Officer |
Jul 29 '24 |
Sale |
0.98 |
1,785 |
1,749 |
79,367 |
2.38%
1.10%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):